Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of August 16th - August 22nd, 2021.
Alerts this week cover papers from New England Journal of Medicine, European Urology, Journal of Immunotherapy of Cancer, ESMO Open and The Lancet.
Dr Morgan also mentions the FDA approval of Nivolumab in the adjuvant treatment of patients with urothelial carcinoma at risk of recurrence after radical resection, regardless of prior neoadjuvant chemotherapy or PDL1 status.
You can watch Dr Morgan's previous roundup here
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer